Serum galactosyltransferase activity was found to be elevated in patients with alcoholic and other liver disorders but remained at a normal level in patients with a variety of nonhepatic diseases. The properties of the galactosyltransferase in patients with liver disease were compared with those of the enzyme in the serum of normal subjects. The possible presence of inhibitors or activators in the serum was examined. Results indicated that in patients with liver disease, the rise in the serum galactosyltransferase was due to an increase in the level of the enzyme present in normal serum and not due to the appearance of a new enzyme. In the cases examined, the level of the enzyme increased with the deterioration of liver function and declined in a patient recovering from acute alcoholic hepatitis. Another glycosyltransferase, an N-acetylgalactosaminyltransferase, was not elevated in the serum of liver disease patients and, unlike the galactosyltransferase, was not detected in normal liver. The results suggest that the serum galactosyltransferase originates from the liver and that an abnormal rise in the level of this enzyme in serum is due to hepatocellular damage.
INTRODUCTION
It is now apparent that in addition to mucins and human blood group substances, immunoglobulins, most serum proteins, and many hormones and enzymes are glycoproteins (1-10), i.e. proteins with varying amount of covalently linked carbohydrate. Such enzymes have been shown to occur in many tissues that synthesize glycoproteins, e.g. liver (11, 12) , gastrointestinal mucosa (13- Received for publication 18 January 1972 and in revised form 6 March 1972. 16 ), submaxillary gland (17, 18) , thyroid gland (19) , and in other tissues and body fluids (20) (21) (22) . In general, these enzymes are membrane bound (11) (12) (13) (14) (15) (16) (17) (18) (19) . Just as defects in glycolipid metabolism have been shown to result in lipid-storage diseases and mucopolysaccharidoses (20) , alterations in glycoprotein metabolism or structure have been implicated in a variety of disorders such as cystic fibrosis, gastric ulcer, gastrointestinal tumors, leukemia, and the microangiopathy of diabetes mellitus (23) (24) (25) (26) (27) (28) (29) . However, the specific abnormalities of glycoprotein metabolism underlying these disorders are unknown at the present time.
Recently, human serum was found to contain several glycosyltransferases, namely, an N-acetylglucosaxminyltransferase (30) , an N-acetylgalactosaminyltransferase (21), a sialyltransferase (22) and a galactosyltransferase (31) . It has also been found that in the case of the N-acetylgalactosaminyltransferase, which catalyzes the transfer of N-acetyl-i-galactosamine to human blood group H-like substances, and which is thus responsible for the human blood group A determinant, the enzyme was present in milk (32) , intestinal tissue (13) and sera (21) of blood group A or AB individuals but was absent in individuals of group B or 0. However, no such variation in the enzyme activity among persons of different blood groups was noted in the case of the sialyltransferase (22) or the galactosyltransferase (31) . Although present in the serum, the source and physiological significance of these enzymes remain unknown.
An examination of glycosyltransferases in the sera of several individuals revealed that one subject had an abnormally high galactosyltransferase level. It was found that this individual also had a liver disorder. Subse- Enzyme assays. For the galactosyltransferase assay, a quantitative assay method utilizing a fetuin acceptor free of N-acetylneuraminic acid and D-galactose was used and is fully described in a previous paper (31) . For the N-acetylgalactosaminyltransferase, a standard assay method (20) was employed using porcine submaxillary mucin or 2'-fucosyllactose as the acceptor. These acceptors both possessed human blood group O(H)-like activity. All enzyme assays were performed under conditions in which the reaction was linear with respect to enzyme concentration and time. Control incubations were performed in the absence of either exogenous acceptor or enzyme, and the sum of amounts of radioactivity incorporated in both controls was subtracted from the total (Fig. 1) . The sera from patients with alcoholic liver disease showed the highest elevations of enzyme activity although variation in the levels was also large. Similar levels and variations were found in viral hepatitis patients and in those with other liver diseases. In contrast, the serum galactosyltransferase activity was not elevated in patients with other disorders: cystic fibrosis, gastric ulcer, carcinoma of the stomach and colon with no evidence of hepatic metastasis, pneumonia, diabetes mellitus, and sickle cell anemia. The results were similar whether the enzyme activity was expressed per milligram of protein or per milliliter of serum. As shown in Table I , the activity of the serum N-acetylgalactosaminyltransferase was not elevated in patients with alcoholic liver disease as distinct from the rise in the galactosyltransferase observed in these patients. Serum glycosyltransferase activities were measured at intervals in a patient (R. S.) with Laennec's cirrhosis, who died of hepatic failure (Fig. 2) , and another (J. M.) who was recovering from acute alcoholic hepatitis (Fig.  3) . In the cirrhosis patient (Fig. 2) the level of the galactosyltransferase activity increased markedly during the period of observation. The N-acetylgalactosaminyltransferase remained at the normal level. In the second case (Fig. 3) , the recovery of liver function, as indicated by a decrease in serum bilirubin and in SGOT,' was accompanied by a drop in serum galactosyltransferase activity to the normal level.
In order to determine whether the presence of an activator or the absence of an inhibitor caused an apparent increase in the level of the serum galactosyltransferase in patients with liver disorders, various proportions of normal and liver disease sera were mixed and the enzyme activity measured (Table II) . The galactosyltransferase activity of each mixture was equivalent to the sum of the individual activities of the two portions. The ratio of experimental to theoretical activity for each mixture was very close to 1; this was within the range of experimental error for the assay procedure. To examine the possible identity of the serum galactosyltransferase from liver disease patients and normal individuals, several properties of the enzyme were investigated (Table III) . The enzyme activity of the serum from both sources was maximal at pH 7.0 to 7.5, 30'C and a manganous ion concentration of 43 mm. The apparent Km for uridine diphosphate galactose (UDPgalactose) of the enzyme from both sources was also very similar.
Electrophoresis of the galactosyltransferase from the sera of normal and alcoholic liver disease individuals was performed for comparison on cellulose acetate strips at pH 4.0 and pH 9.0 as described in Methods. The results are shown in Fig. 4 . At either pH value the enzyme from normal and liver disease subjects migrated the same distance from the origin and moved at a slower rate than serum albumin. Only a single peak of enzyme activity was ever observed.
The levels of both glycosyltransferases were measured in autopsy specimens of liver and intestine. The results are shown in Table IV . The galactosyltransferase was very active in both tissues. However, the N-acetylgalactosaminyltransferase activity, while high in the intestinal tissue, was at the limit of detection in the liver. DISCUSSION Two glycosyltransferases were examined in this report, a galactosyltransferase and an N-acetylgalactosaminyltransferase. The reactions catalyzed by these two enzymes are shown in Fig. 5 . The galactosyltransferase was found to be present in the serum of all individuals (31); as reported previously (21) the N-acetylgalactosaminyltransferase is present only in individuals of blood group A and AB and is believed to be responsible for the formation of the blood group A determinant. Although these enzymes were also detected in the erythrocyte membrane (21, 31) , the levels of the membrane enzymes were not measured in this study.
A significant elevation in serum galactosyltransferase activity occurred in patients with active liver diseases, regardless of etiology. Alcoholic liver diseases, i.e., fatty liver or alcoholic hepatitis, viral hepatitis, cholestatic liver disease secondary to common duct stones and hepatic metastases from gastrointestinal cancer all resulted in the elevation of this enzyme. In addition, the activity of the galactosyltransferase rose with the levels of other indicators of liver dysfunction, e.g., serum bilirubin and SGOT. As depicted in Fig. 2 , a patient with advanced Laennec's cirrhosis, who eventually died of hepatic decompensation, showed a progressive rise in the serum galactosyltransferase. This rise was concomitant with a clinical deterioration in liver function. Conversely, during recovery from acute alcoholic hepatitis (Fig. 3 ) the level of this enzyme returned to normal, coincident with the improvement in liver function as judged by a fall in serum bilirubin and SGOT. Patients with a variety of nonhepatic disorders showed no increase in the serum galactosyltransferase activity, suggesting that the elevation of this enzyme may occur only in patients with liver diseases, though the number of observations in patients with extrahepatic disease was not large.
The increase in serum galactosyltransferase activity observed in patients with active liver disease is apparently not due to the presence of an activator or the absence of an inhibitor in the serum, since mixtures of normal and pathological sera in different proportions yielded the expected additive enzyme activity. Electrophoresis of the serum at pH 4.0 and 9.0 of a normal subject and of a patient with alcoholic liver disease showed a single band of galactosyltransferase activity. The electrophoretic mobility of the enzyme from normal and liver disease sera was the same. The identity of pH, temperature, and Mn' ion concentration required for maximal activity and the similarity of the apparent Km for UDPgalactose in normal individuals and in patients with liver disease all suggest that the serum enzyme present in the liver disease patients is probably the same enzyme as that in the normal subjects. Unlike the galactosyltransferase, the level of the N-acetylgalactosaminyltransferase did not rise in the serum of blood group A and AB patients with liver disease but remained the same as in the normal subjects. Presuming the liver is the source of the serum galactosyltransferase, as suggested by the rise in the enzyme during liver disorders, it would be surprising if the N-acetylgalactosaminyltransferase increased, since this organ showed a very low level of N-acetylgalactosaminyltransferase activity in normal patients.
It is possible that the elevation of the galactosyltransferase in the serum of patients with liver disorders is either due to detachment of the membrane enzymes from damaged cells or to a regeneration process in the liver. Roseman (34) has suggested that a galactosyltransferase plays an important role in the aggregation of embryonic retinal cells and Den, Kaufman, and Roseman (35) reported an activity of this enzyme in the serum and cerebral spinal fluid of the embryonic chick greater than that in the adult. However, the rise of the galactosyltransferase is probably not due to a regenerative process since patients with obstructive jaundice due to gallstones and hepatic congestion due to heart failure had an elevated level of this enzyme in serum. Since the enzyme is membrane-bound in liver (11, 12) and in other tissues (14, (1) Galactosyltransferase:
UDP-Gal + GlcNAc-glycoprotein -) Gal-GIcNAc-glycoprotein + (UDP) Fucosyllactose) )-GalNAc-Gal-Glc + (UDP) Fuc Fuc FIGURE 5 Summary of the reactions catalyzed by the galactosyltransferase and the N-acetylgalactosaminyltransferase. UDP-Gal, uridine diphosphate galactose; UDP-GalNAc, uridine diphosphate N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; Gal, galactose; Fuc, fucose; Glc, glucose. 
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